Thought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet
Thought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet The Zayed Prize for Sustainable Development, the UAE’s pioneering prize…
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Ligand Pharmaceuticals Incorporated announced that…
Datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful progression-free survival benefits in patients with HR-positive, HER2-low, or negative breast cancer in the TROPION-Breast01 Phase III trial
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low, or negative breast cancer in TROPION-Breast01 Phase III trial Positive high-level results from the TROPION-Breast01…
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer Bristol Myers Squibb today announced the…
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer Merck (NYSE: MRK), known as…
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase…
A suit of armor for cancer-fighting cells
A suit of armor for cancer-fighting cells In recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results,…
Biocytogen officially launches the RenMice
Biocytogen officially launches the RenMice Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) officially announces the RenMice ® series , which includes a collection of independently developed fully human antibody mice and TCR…
Emulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment
Emulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment Emulate, Inc., the leading provider of next-generation in vitro models, today announced the publication…
Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML
Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML Daiichi Sankyo announced that quizartinib has been recommended for approval in the European Union (EU)…
Merck Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy Merck…
EBGLYSS Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis The positive CHMP opinion is now being reviewed by the European Commission (EC). The approval of this biologic in the European…